Mid Cap Stocks To Add to Your Watchlist - April 27th

Key Points

• MarketBeat's screener flagged ProShares UltraPro Short QQQ (SQQQ), Organon & Co. (OGN) and Arcellx (ACLX) as mid-cap stocks to watch based on the highest recent dollar trading volume.
• SQQQ is a leveraged inverse fund that seeks daily results equal to three times the inverse of the NASDAQ-100, making it a bearish/hedging tool for traders.
• Arcellx is developing ddCAR immunotherapies, with its lead candidate anitocabtagene autoleucel currently in a Phase 2 trial for relapsed or refractory multiple myeloma.

ProShares UltraPro Short QQQ, Organon & Co., and Arcellx are the three Mid Cap stocks to watch today, according to MarketBeat's stock screener tool. Mid-cap stocks are shares of companies with a medium-sized market capitalization, typically ranging from about $2 billion to $10 billion (exact cutoffs vary by index and provider). They generally offer a balance between growth potential and stability—often more growth upside than large-cap firms but less volatility and risk than small-cap companies. These companies had the highest dollar trading volume of any Mid Cap stocks within the last several days.

ProShares UltraPro Short QQQ (SQQQ)

ProShares UltraPro Short QQQ (the Fund) seeks daily investment results, which corresponds to three times the inverse of the daily performance of the NASDAQ-100 Index (the Index). The Index includes 100 of the non-financial domestic and international issues listed on National Association of Securities Dealers Automated Quotation (NASDAQ) Stock Market.

Read Our Latest Research Report on SQQQ

Organon & Co. (OGN)

Read Our Latest Research Report on OGN

Arcellx (ACLX)

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).

Read Our Latest Research Report on ACLX

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.